Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on January 10, 2022, to disclose preliminary financial and operational updates provided at the 40th Annual J.P. Morgan Healthcare Conference. The key takeaway for investors is the strong performance of two of its major products. U.S. net product sales for EYLEA® (aflibercept) Injection reached approximately $5.79 billion for the full year 2021, with $1.54 billion in the fourth quarter alone. Furthermore, REGEN-COV® (casirivimab and imdevimab) demonstrated exceptional sales, generating approximately $5.82 billion for the full year 2021, including a significant $2.29 billion in the fourth quarter. These preliminary figures highlight substantial revenue contributions from these key therapies and provide investors with an early look at the company's recent performance ahead of official earnings releases.
Key Highlights
- 1Regeneron provided preliminary 2021 full-year U.S. net product sales for EYLEA® of approximately $5.79 billion.
- 2Preliminary fourth quarter 2021 U.S. net product sales for EYLEA® were approximately $1.54 billion.
- 3Regeneron reported preliminary 2021 full-year U.S. net product sales for REGEN-COV® of approximately $5.82 billion.
- 4Preliminary fourth quarter 2021 U.S. net product sales for REGEN-COV® reached approximately $2.29 billion.
- 5The information was presented by Regeneron's CEO and CSO at the 40th Annual J.P. Morgan Healthcare Conference.
- 6This 8-K filing incorporates information from a presentation furnished as Exhibit 99.1.